Travere Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Travere Therapeutics (TVTX) will present data at ASN Kidney Week 2026. FILSPARI (sparsentan) showed 75% complete proteinuria remission in IgAN and better outcomes than irbesartan in FSGS. Key data: 75% remission, eGFR stabilization, and lower kidney failure rates.
Travere Therapeutics (TVTX) will present data on FILSPARI at ASN 2026, showing 75% remission in IgAN and slower eGFR decline in FSGS. The studies also indicate greater proteinuria reduction compared to irbesartan. According to the company, these results reinforce FILSPARI's effectiveness in these indications.
Travere Therapeutics (TVTX) received a patent extension for FILSPARI, protecting its use in focal segmental glomerulosclerosis until October 2037. The company's stock has shown mixed performance, down 9.49% over 30 days but up 51.80% year-to-date. Analysts debate its valuation, with some seeing it as 19% undervalued at $59.99, while others note its higher P/S ratio compared to peers.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning TVTX (Travere Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent TVTX coverage spans financial news, insider activity and corporate actions.
In the last 30 days, TVTX insiders filed 40 SEC Form 4 transactions — no purchases and 40 sales ($66.3M). The most active reporter was Dube Eric M, CHIEF EXECUTIVE OFFICER, with 8 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive trial outcomes suggest stronger market demand for FILSPARI.
Positive trial data likely lifts TVTX share price.
The patent extension reduces near-term risk to the FILSPARI franchise and may support a higher valuation.
HC Wainwright & Co. maintained a Buy rating on Travere Therapeutics (TRVRS) with a $67 price target, suggesting a 6.6% upside from the Sep 21 close. The firm cited strong leadership transition and confidence in product execution as key reasons for their rating.
Leadership change may affect strategic direction and investor sentiment, potentially pressuring the stock in the short term.
AlphAI scores every news story that mentions TVTX with an AI model for sentiment and relevance, and aggregates insider trades from Travere Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Travere Therapeutics (TVTX) will present data at ASN Kidney Week 2026. FILSPARI (sparsentan) showed 75% complete proteinuria remission in IgAN and better outcomes than irbesartan in FSGS. Key data: 75% remission, eGFR stabilization, and lower kidney failure rates.
2 min readTravere Therapeutics (TVTX) will present data on FILSPARI at ASN 2026, showing 75% remission in IgAN and slower eGFR decline in FSGS. The studies also indicate greater proteinuria reduction compared to irbesartan. According to the company, these results reinforce FILSPARI's effectiveness in these indications.
1 min readTravere Therapeutics (TVTX) received a patent extension for FILSPARI, protecting its use in focal segmental glomerulosclerosis until October 2037. The company's stock has shown mixed performance, down 9.49% over 30 days but up 51.80% year-to-date. Analysts debate its valuation, with some seeing it as 19% undervalued at $59.99, while others note its higher P/S ratio compared to peers.
2 min readHC Wainwright & Co. maintained a Buy rating on Travere Therapeutics (TRVRS) with a $67 price target, suggesting a 6.6% upside from the Sep 21 close. The firm cited strong leadership transition and confidence in product execution as key reasons for their rating.
1 min readTravere Therapeutics (TVTX) shares dropped 2.3% after-hours on news of CEO Eric Dube's planned departure in December 2026. Bradley Campbell, former Amicus Therapeutics CEO, will succeed Dube. Dube will stay as advisor until February 2027. The board praised Campbell's experience in rare disease therapies.
2 min readTravere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b)(c)(d) On September 21, 2026, Travere Therapeutics, Inc. (the “Company”) and Eric Dube, Ph.D., mutually agreed to the ti
1 min readROTE WILLIAM E. (Chief Research Officer) sold 209,048 shares of Travere Therapeutics, Inc. (TVTX) at an average of $62.83 ($61.99–$65.31, $13.14M total) across 6 trades over 2026-09-15 to 2026-09-16 under a Rule 10b5-1 trading plan.
1 min readHeerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 283,189 shares of Travere Therapeutics, Inc. (TVTX) at an average of $63.06 ($62.05–$65.31, $17.86M total) across 7 trades over 2026-09-15 to 2026-09-17 under a Rule 10b5-1 trading plan.
1 min readInrig Jula (EVP, Head of R&D & CMO) sold 44,674 shares of Travere Therapeutics, Inc. (TVTX) at an average of $62.34 ($62.02–$65.31, $2.79M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readREED ELIZABETH E (Chief Legal Officer and GC) sold 37,500 shares of Travere Therapeutics, Inc. (TVTX) at an average of $62.34 ($62.03–$65.31, $2.34M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min read
